መነሻ › አኩት ባይፊኖታይፒክ ሊውኬሚያ › ማሳቹሴትስ
በማሳቹሴትስ ለአኩት ባይፊኖታይፒክ ሊውኬሚያ የሚደረጉ ክሊኒካዊ ጥናቶች
ለአኩት ባይፊኖታይፒክ ሊውኬሚያ የሚደረጉ 5 ጥናቶች በማሳቹሴትስ ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።
በማሳቹሴትስ ውስጥ ያሉ ከተሞች
Official study text (English)
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Dana-Farber Cancer Institute, Boston
- UMass Memorial Medical Center - University Campus, Worcester
ተሳታዮችን በመፈለግ ላይደረጃ 2
365 Days · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT06317662Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
- Baystate Medical Center, Springfield
- እና 1 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
365 Days – 25 Years · ሁሉም ጾታዎች · የተሻሻለው በ25 ኦገስ 2026 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Dana-Farber Cancer Institute, Boston
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እስከ እድሜ 22 · ሁሉም ጾታዎች · የተሻሻለው በ25 ኦገስ 2026 · NCT04726241Venetoclax Basket Trial for High Risk Hematologic Malignancies
- Dana-Farber Cancer Institute, Boston
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ ከ1 እስከ 40 · ሁሉም ጾታዎች · የተሻሻለው በ12 ማርች 2026 · NCT05292664Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Dana-Farber Cancer Institute, Boston
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ ከ1 እስከ 21 · ሁሉም ጾታዎች · የተሻሻለው በ6 ዲሴም 2024 · NCT05476770ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።